ArticleCureus2025
Caplacizumab in Lupus-Associated Thrombotic Thrombocytopenic Purpura (TTP): Navigating Autoimmunity and Microangiopathy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombotic thrombocytopenic purpura (TTP) is a rare but potentially life-threatening complication associated with systemic lupus erythematosus (SLE). This condition is characterized by microangiopathic hemolytic anemia and thrombocytopenia, which can result from either an acquired deficiency of the ADAM metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS13) or through complement-mediated mechanisms. We present the case of a 55-year-old female with a history of Sjögren's disease and a recent diagnosis of SLE. She exhibited severe anemia, thrombocytopenia, and symptoms suggestive of immune-mediated TTP with markedly reduced ADAMTS13 activity. Her diagnosis was confirmed through clinical evaluations, laboratory tests, and immunologic findings. After initially responding to urgent therapy with plasmapheresis, high-dose corticosteroids, and rituximab, the addition of caplacizumab led to a rapid and sustained improvement in her thrombocytopenia. This report highlights the successful use of caplacizumab in lupus-associated immune TTP and reviews diagnostic and therapeutic challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.